The ZNF22 antibody targets the zinc finger protein 22 (ZNF22), a member of the Krüppel-associated box (KRAB) domain-containing zinc finger protein (ZNF) family. ZNF22. also known as KOX15. is encoded by the *ZNF22* gene in humans (chromosome 10q11.2) and plays roles in transcriptional regulation, particularly as a transcriptional repressor. Its structure includes a conserved N-terminal KRAB domain, which mediates protein-protein interactions, and C-terminal zinc finger motifs that bind DNA sequences to regulate gene expression. ZNF22 is implicated in cellular processes such as differentiation, apoptosis, and chromatin remodeling.
Antibodies against ZNF22 are primarily used in research to study its expression patterns, subcellular localization (typically nuclear), and interactions with other proteins or DNA. These antibodies enable techniques like Western blotting, immunohistochemistry, and chromatin immunoprecipitation (ChIP). Studies suggest ZNF22 may have tissue-specific functions and potential links to diseases, including certain cancers and neurological disorders, though its precise pathological roles remain under investigation. Commercial ZNF22 antibodies are often validated for specificity using knockout controls or siRNA-mediated knockdown. Research into ZNF22 and its antibodies contributes to understanding the broader role of KRAB-ZNF proteins in development, epigenetics, and disease mechanisms.